We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
View Top Employees from GalapagosWebsite | http://www.glpg.com |
Ticker | GLPG |
Revenue | $22.9 billion |
Funding | $295.5 million |
Employees | 1,262 (1,262 on RocketReach) |
Founded | 1999 |
Address | l11 a3 Generaal De Wittelaan, Mechelen, Flanders 2800, BE |
Phone | (321) 534-2900 |
Fax | (321) 534-2901 |
Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Healthcare, Biotechnology, Health Care, Science and Engineering, Clinical Trials, Medical |
Web Rank | 690412 |
Web Visits | 54280 |
Keywords | Biotechnology, Immunology, Small Molecule Drug Discovery, Oncology |
SIC | SIC Code 28 Companies, SIC Code 873 Companies, SIC Code 87 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 62151 Companies, NAICS Code 5417 Companies, NAICS Code 325 Companies, NAICS Code 621 Companies, NAICS Code 541 Companies, NAICS Code 6215 Companies, NAICS Code 541711 Companies, NAICS Code 62 Companies, NAICS Code 54 Companies, NAICS Code 32 Companies |
Looking for a particular Galapagos employee's phone or email?
The Galapagos annual revenue was $22.9 billion in 2024.
1,262 people are employed at Galapagos.
Galapagos is based in Mechelen, Flanders.
The NAICS codes for Galapagos are [54171, 62151, 5417, 325, 621, 541, 6215, 541711, 62, 54, 32].
The SIC codes for Galapagos are [28, 873, 87, 283].